Vyant Bio to Participate at Neuroscience 2022, the 52nd Annual Gathering of the Society for Neuroscience, on November 12-16 CHERRY HILL, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...

Vyant Bio Announces One-for-Five Reverse Stock Split CHERRY HILL, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...

Vyant Bio Reports Second Quarter and First Half 2022 Results and Provides Strategic and Business Highlights Conference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights Based on preclinical efficacy data in our human Rett cortical organoid model, we are advancing VYNT0126 into...

Vyant Bio to Present at the Q4 Investor Summit Micro & Small Cap Conference Cherry Hill, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...

Vyant Bio Announces Investor Conference Call and Webcast for the Third Quarter 2021 CHERRY HILL, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...